Glatiramer Acetate Reverses Motor Dysfunction and the Decrease in Tyrosine Hydroxylase Levels in a Mouse Model of Parkinson's Disease

Madeline J. Churchill, Mark A. Cantu, Ella A. Kasanga, C. Moore, Michael Francis Salvatore, Charles K. Meshul

Research output: Contribution to journalArticle

Abstract

Parkinson's disease (PD) is the second most common neurodegenerative disease and there are no effective treatments that either slow or reverse the degeneration of the dopamine (DA) pathway. Using a 4-week progressive MPTP (1-methyl-1,2,3,6-tetrahydropyridine) neurotoxin model of PD, which is characterized by neuroinflammation, loss of nigrostriatal DA, and motor dysfunction, as seen in patients with PD, we tested whether post-MPTP treatment with glatiramer acetate (GA), an immunomodulatory drug, could reverse these changes. GA restored the grip dysfunction and gait abnormalities that were evident in the MPTP treated group. The reversal of the motor dysfunction was attributable to the substantial recovery in tyrosine hydroxylase (TH) protein expression in the striatum. Within the substantia nigra pars compacta, surface cell count analysis showed a slight increase in TH + cells following GA treatment in the MPTP group, which was not statistically different from the vehicle (VEH) group. This was associated with the recovery of BDNF (brain derived neurotrophic factor) protein levels and a reduction in the microglial marker, IBA1, protein expression within the midbrain. Alpha synuclein (syn-1) levels within the midbrain and striatum were decreased following MPTP, while GA facilitated recovery to VEH levels in the striatum in the MPTP group. Although DA tissue analysis revealed no significant increase in striatal DA or 3,4-Dihydroxyphenylacetic acid levels (DOPAC) in the MPTP group treated with GA, DA turnover (DOPAC/DA) recovered back to VEH levels following GA treatment. GA treatment effectively reversed clinical (motor dysfunction) and pathology (TH, IBA1, BDNF expression) of PD in a murine model.

Original languageEnglish
Pages (from-to)8-27
Number of pages20
JournalNeuroscience
Volume414
DOIs
StatePublished - 21 Aug 2019

Fingerprint

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
Tyrosine 3-Monooxygenase
Parkinson Disease
Dopamine
3,4-Dihydroxyphenylacetic Acid
Brain-Derived Neurotrophic Factor
Mesencephalon
Therapeutics
Corpus Striatum
alpha-Synuclein
Nerve Growth Factors
Neurotoxins
Hand Strength
Glatiramer Acetate
Gait
Neurodegenerative Diseases
Proteins
Cell Count
Pathology
Pharmaceutical Preparations

Keywords

  • MPTP
  • Motor recovery
  • Parkinson's disease
  • glatiramer acetate
  • neuroinflammation
  • neurotrophic factors

Cite this

Churchill, Madeline J. ; Cantu, Mark A. ; Kasanga, Ella A. ; Moore, C. ; Salvatore, Michael Francis ; Meshul, Charles K. / Glatiramer Acetate Reverses Motor Dysfunction and the Decrease in Tyrosine Hydroxylase Levels in a Mouse Model of Parkinson's Disease. In: Neuroscience. 2019 ; Vol. 414. pp. 8-27.
@article{bc00e802a0374749b2aa40fbff8a70a9,
title = "Glatiramer Acetate Reverses Motor Dysfunction and the Decrease in Tyrosine Hydroxylase Levels in a Mouse Model of Parkinson's Disease",
abstract = "Parkinson's disease (PD) is the second most common neurodegenerative disease and there are no effective treatments that either slow or reverse the degeneration of the dopamine (DA) pathway. Using a 4-week progressive MPTP (1-methyl-1,2,3,6-tetrahydropyridine) neurotoxin model of PD, which is characterized by neuroinflammation, loss of nigrostriatal DA, and motor dysfunction, as seen in patients with PD, we tested whether post-MPTP treatment with glatiramer acetate (GA), an immunomodulatory drug, could reverse these changes. GA restored the grip dysfunction and gait abnormalities that were evident in the MPTP treated group. The reversal of the motor dysfunction was attributable to the substantial recovery in tyrosine hydroxylase (TH) protein expression in the striatum. Within the substantia nigra pars compacta, surface cell count analysis showed a slight increase in TH + cells following GA treatment in the MPTP group, which was not statistically different from the vehicle (VEH) group. This was associated with the recovery of BDNF (brain derived neurotrophic factor) protein levels and a reduction in the microglial marker, IBA1, protein expression within the midbrain. Alpha synuclein (syn-1) levels within the midbrain and striatum were decreased following MPTP, while GA facilitated recovery to VEH levels in the striatum in the MPTP group. Although DA tissue analysis revealed no significant increase in striatal DA or 3,4-Dihydroxyphenylacetic acid levels (DOPAC) in the MPTP group treated with GA, DA turnover (DOPAC/DA) recovered back to VEH levels following GA treatment. GA treatment effectively reversed clinical (motor dysfunction) and pathology (TH, IBA1, BDNF expression) of PD in a murine model.",
keywords = "MPTP, Motor recovery, Parkinson's disease, glatiramer acetate, neuroinflammation, neurotrophic factors",
author = "Churchill, {Madeline J.} and Cantu, {Mark A.} and Kasanga, {Ella A.} and C. Moore and Salvatore, {Michael Francis} and Meshul, {Charles K.}",
year = "2019",
month = "8",
day = "21",
doi = "10.1016/j.neuroscience.2019.06.006",
language = "English",
volume = "414",
pages = "8--27",
journal = "Neuroscience",
issn = "0306-4522",
publisher = "Elsevier Ltd",

}

Glatiramer Acetate Reverses Motor Dysfunction and the Decrease in Tyrosine Hydroxylase Levels in a Mouse Model of Parkinson's Disease. / Churchill, Madeline J.; Cantu, Mark A.; Kasanga, Ella A.; Moore, C.; Salvatore, Michael Francis; Meshul, Charles K.

In: Neuroscience, Vol. 414, 21.08.2019, p. 8-27.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Glatiramer Acetate Reverses Motor Dysfunction and the Decrease in Tyrosine Hydroxylase Levels in a Mouse Model of Parkinson's Disease

AU - Churchill, Madeline J.

AU - Cantu, Mark A.

AU - Kasanga, Ella A.

AU - Moore, C.

AU - Salvatore, Michael Francis

AU - Meshul, Charles K.

PY - 2019/8/21

Y1 - 2019/8/21

N2 - Parkinson's disease (PD) is the second most common neurodegenerative disease and there are no effective treatments that either slow or reverse the degeneration of the dopamine (DA) pathway. Using a 4-week progressive MPTP (1-methyl-1,2,3,6-tetrahydropyridine) neurotoxin model of PD, which is characterized by neuroinflammation, loss of nigrostriatal DA, and motor dysfunction, as seen in patients with PD, we tested whether post-MPTP treatment with glatiramer acetate (GA), an immunomodulatory drug, could reverse these changes. GA restored the grip dysfunction and gait abnormalities that were evident in the MPTP treated group. The reversal of the motor dysfunction was attributable to the substantial recovery in tyrosine hydroxylase (TH) protein expression in the striatum. Within the substantia nigra pars compacta, surface cell count analysis showed a slight increase in TH + cells following GA treatment in the MPTP group, which was not statistically different from the vehicle (VEH) group. This was associated with the recovery of BDNF (brain derived neurotrophic factor) protein levels and a reduction in the microglial marker, IBA1, protein expression within the midbrain. Alpha synuclein (syn-1) levels within the midbrain and striatum were decreased following MPTP, while GA facilitated recovery to VEH levels in the striatum in the MPTP group. Although DA tissue analysis revealed no significant increase in striatal DA or 3,4-Dihydroxyphenylacetic acid levels (DOPAC) in the MPTP group treated with GA, DA turnover (DOPAC/DA) recovered back to VEH levels following GA treatment. GA treatment effectively reversed clinical (motor dysfunction) and pathology (TH, IBA1, BDNF expression) of PD in a murine model.

AB - Parkinson's disease (PD) is the second most common neurodegenerative disease and there are no effective treatments that either slow or reverse the degeneration of the dopamine (DA) pathway. Using a 4-week progressive MPTP (1-methyl-1,2,3,6-tetrahydropyridine) neurotoxin model of PD, which is characterized by neuroinflammation, loss of nigrostriatal DA, and motor dysfunction, as seen in patients with PD, we tested whether post-MPTP treatment with glatiramer acetate (GA), an immunomodulatory drug, could reverse these changes. GA restored the grip dysfunction and gait abnormalities that were evident in the MPTP treated group. The reversal of the motor dysfunction was attributable to the substantial recovery in tyrosine hydroxylase (TH) protein expression in the striatum. Within the substantia nigra pars compacta, surface cell count analysis showed a slight increase in TH + cells following GA treatment in the MPTP group, which was not statistically different from the vehicle (VEH) group. This was associated with the recovery of BDNF (brain derived neurotrophic factor) protein levels and a reduction in the microglial marker, IBA1, protein expression within the midbrain. Alpha synuclein (syn-1) levels within the midbrain and striatum were decreased following MPTP, while GA facilitated recovery to VEH levels in the striatum in the MPTP group. Although DA tissue analysis revealed no significant increase in striatal DA or 3,4-Dihydroxyphenylacetic acid levels (DOPAC) in the MPTP group treated with GA, DA turnover (DOPAC/DA) recovered back to VEH levels following GA treatment. GA treatment effectively reversed clinical (motor dysfunction) and pathology (TH, IBA1, BDNF expression) of PD in a murine model.

KW - MPTP

KW - Motor recovery

KW - Parkinson's disease

KW - glatiramer acetate

KW - neuroinflammation

KW - neurotrophic factors

UR - http://www.scopus.com/inward/record.url?scp=85068746509&partnerID=8YFLogxK

U2 - 10.1016/j.neuroscience.2019.06.006

DO - 10.1016/j.neuroscience.2019.06.006

M3 - Article

C2 - 31220543

AN - SCOPUS:85068746509

VL - 414

SP - 8

EP - 27

JO - Neuroscience

JF - Neuroscience

SN - 0306-4522

ER -